TrialScientific reports2016

A double-blind, randomised, placebo-controlled trial of Ganoderma lucidum for the treatment of cardiovascular risk factors of metabolic syndrome.

Nerida L Klupp et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.